Table 1 Disease characteristics and biomarker levels at baseline*
Placebo→Infliximab 6 mg/kg + MTX | Infliximab 3 mg/kg + MTX | |
|---|---|---|
Patients included in substudy | 38 | 34 |
Age at study entry, yrs | 12.7 (3.3) | 13.4 (2.8) |
Disease characteristics | ||
Disease duration, yrs | 4.03 (3.92) | 4.89 (4.4) |
Number of joints with active arthritis | ||
n | 38 | 34 |
Range | (5.0, 47.9) | (5.0, 44.0) |
Median | 16.0 | 13.5 |
Number of joints with limited range of motion | ||
n | 38 | 34 |
Range | (4.0, 48.4) | (2.0, 42.0) |
Median | 15.0 | 12.5 |
Inflammatory markers | ||
C-reactive protein, mg/dL | ||
n | 38 | 34 |
Range | (0.4, 7.4) | (0.4, 10.5) |
Median | 0.8 | 0.9 |
TNF-α (pg/mL) | ||
n | 14 | 9 |
Range | (1.6, 30.9) | (1.6, 24.4) |
Median | 1.6 | 1.6 |
IL-6 (pg/mL) | ||
n | 28 | 27 |
Range | (0.4, 93.7) | (0.1, 79.3) |
Median | 8.2 | 3.4 |
MMP-3 (ng/mL) | ||
n | 32 | 32 |
Range | (2.7, 390.2) | (0.8, 570.0) |
Median | 39.3 | 40.3 |
ICAM-1 (ng/mL) | ||
n | 34 | 32 |
Range | (200.2, 767.9) | (18.6, 1059.2) |
Median | 394.0 | 375.4 |
VEGF (ng/mL) | ||
n | 33 | 32 |
Range | (83.3, 1535.2) | (29.8, 1447.0) |
Median | 440.2 | 317.8 |
IL-12p40 (pg/mL) | ||
n | 34 | 30 |
Range | (15.5, 357.9) | (15.6, 357.9) |
Median | 84.3 | 95.6 |